

# ASTELLAS PHARMA INC.

ISIN: JP3942400007 WKN: 4503 Asset Class: Stock

## Company

2024/05/02 08:00:00



**Price**  
**1,558.00**  
JPY

**Difference** ▲ 2.16%(33.00)



## Contact Details

ASTELLAS PHARMA INC. Tel: +81-3-3244-3000  
 -- Fax: +  
 2-5-1 Nihonbashi-Honcho, Chuo-Ku Web: <http://www.astellas.com>  
 103-8411 Tokyo E-mail: -

## Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

## Financial figures, Fiscal year: from 01.04. to 31.03.

| Financial figures                     | 2024              |                        | 2023              |                        | 2022              |                        |
|---------------------------------------|-------------------|------------------------|-------------------|------------------------|-------------------|------------------------|
|                                       | Assets            | Liabilities and equity | Assets            | Liabilities and equity | Assets            | Liabilities and equity |
| <b>Current assets</b>                 | 1,194,730,000,000 |                        | 1,049,954,000,000 |                        | 923,354,000,000   |                        |
| <b>Common stock capital</b>           |                   | 103,001,000,000        |                   | 103,001,000,000        |                   | 103,001,000,000        |
| <b>Fixed assets</b>                   | 2,374,873,000,000 |                        | 1,406,564,000,000 |                        | 1,409,041,000,000 |                        |
| <b>Equity capital of a company</b>    |                   | 1,595,988,000,000      |                   | 1,507,954,000,000      |                   | 1,460,308,000,000      |
| <b>Cash and cash equivalents</b>      | 335,687,000,000   |                        | 376,840,000,000   |                        | 315,986,000,000   |                        |
| <b>Accrued liabilities</b>            |                   | 32,043,000,000         |                   | 67,859,000,000         |                   | 77,207,000,000         |
| <b>Other assets</b>                   | -                 |                        | -                 |                        | -                 |                        |
| <b>Current liabilities</b>            |                   | 1,285,725,000,000      |                   | 726,034,000,000        |                   | 687,411,000,000        |
| <b>Prepayments and accrued income</b> | -                 |                        | -                 |                        | -                 |                        |
| <b>Non-current liabilities</b>        |                   | 687,890,000,000        |                   | 222,530,000,000        |                   | 184,675,000,000        |
| <b>Different income</b>               |                   | -                      |                   | -                      |                   | -                      |
| <b>Other liabilities</b>              |                   | 156,763,000,000        |                   | 37,162,000,000         |                   | 46,631,000,000         |
| <b>Total assets</b>                   | 3,569,603,000,000 | 3,569,603,000,000      | 2,456,518,000,000 | 2,456,518,000,000      | 2,332,395,000,000 | 2,332,395,000,000      |

## Balance notes

|                            | 2024    | 2023   | 2022   |
|----------------------------|---------|--------|--------|
| <b>Accounting standard</b> | IFRS    | IFRS   | IFRS   |
| <b>Employees</b>           | -       | 14,484 | 14,522 |
| <b>Equity ratio</b>        | 44.71%  | 61.39% | 62.61% |
| <b>Debt-equity ratio</b>   | 123.66% | 62.90% | 59.72% |

## Others

|                         | 2024   | 2023   | 2022   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 28.17% | 25.66% | 20.97% |

# ASTELLAS PHARMA INC.

ISIN: JP3942400007 WKN: 4503 Asset Class: Stock

## Income statement

|   | 2024              | 2023              | 2022              |
|---|-------------------|-------------------|-------------------|
| Turnover  | 1,603,672,000,000 | 1,518,619,000,000 | 1,296,163,000,000 |
| Net income  | 17,045,000,000    | 98,714,000,000    | 124,086,000,000   |
| EBIT  | 172,104,000       | 777,072,000       | 963,312,000       |
| Operating income before taxes                                 | 28,134,000,000    | 131,101,000,000   | 156,397,000,000   |
| Cash Flow   | 181,325,000,000   | 332,325,000,000   | 258,160,000,000   |
| Net interest income   | -550,000,000      | 1,589,000,000     | -4,155,000,000    |
| Research and development expenses                             | 294,187,000,000   | 276,128,000,000   | 246,010,000,000   |
| Income taxes  | 7,924,000,000     | 33,647,000,000    | 32,800,000,000    |
| Result from investments in subsidiaries, associates and other | -3,165,000,000    | 1,260,000,000     | 489,000,000       |
| Revenues per employee   | -                 | 629,088           | 535,531           |

## Board of Directors

|                   |                               |
|-------------------|-------------------------------|
| Kenji Yasukawa    | Chairman of Supervisory Board |
| Eriko Sakurai     | Member of Supervisory Board   |
| Haruko Shibumura  | Member of Supervisory Board   |
| Hiroko Sakai      | Member of Supervisory Board   |
| Hiroo Sasaki      | Member of Supervisory Board   |
| Hiroshi Kawabe    | Member of Supervisory Board   |
| Katsuyoshi Sugita | Member of Supervisory Board   |
| Mamoru Sekiyama   | Member of Supervisory Board   |
| Mika Nakayama     | Member of Supervisory Board   |
| Noriyuki Uematsu  | Member of Supervisory Board   |
| Takashi Tanaka    | Member of Supervisory Board   |
| Tatsuro Ishizuka  | Member of Supervisory Board   |
| Tomokazu Fujisawa | Member of Supervisory Board   |

## Members of Management Board

|                    |                               |
|--------------------|-------------------------------|
| Kenji Yasukawa     | Chairman of Managing Board    |
| Bernie Zeiher      | Member of Executive Committee |
| Catherine Levitt   | Member of Executive Committee |
| Fumiaki Sakurai    | Member of Executive Committee |
| Hideki Shima       | Member of Executive Committee |
| Minoru Kikuoka     | Member of Executive Committee |
| Naoki Okamura      | Member of Executive Committee |
| Yoshihitsu Shitaka | Member of Executive Committee |
| Yukio Matsui       | Member of Executive Committee |